Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)

Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)

Abstract only

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2024-04, Vol.102 (17_supplement_1)
Hauptverfasser: Giovannoni, Gavin, Granziera, Cristina, Mao-Draayer, Yang, Cutter, Gary, Kalbus, Oleksandr, Staikov, Ivan, Dufek, Michal, Saubadu, Stephane, Bejuit, Raphael, Djukic, Biljana, Truffinet, Philippe, Wallstroem, Erik, Vermersch, Patrick
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 17_supplement_1
container_start_page
container_title Neurology
container_volume 102
creator Giovannoni, Gavin
Granziera, Cristina
Mao-Draayer, Yang
Cutter, Gary
Kalbus, Oleksandr
Staikov, Ivan
Dufek, Michal
Saubadu, Stephane
Bejuit, Raphael
Djukic, Biljana
Truffinet, Philippe
Wallstroem, Erik
Vermersch, Patrick
description Abstract only
doi_str_mv 10.1212/WNL.0000000000205036
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1212_WNL_0000000000205036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1212_WNL_0000000000205036</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1212_WNL_00000000002050363</originalsourceid><addsrcrecordid>eNqdjzFPwzAQhS0EEqHwDxhuhMHFdtoksKJUDEARQYLNcsOZGlwn8gXRrPxyjIQYGHnLSe_dnd7H2LEUU6mkOnu8vZ6KXykxF3mxwzI5VwUvcvW0y7JkVzyvymqfHRC9CpHC8jxjn42xOIxgwjPU1rrWtCN0FhYRt8a7jVmBC3CP3vTkwgvcvPvB9R6haT3GjhxdwKziH4hvaYtSSmBjt4FhjXC3NoSgYNlj4N6s0EO9HTCQ6wKcNLlMrcvTQ7ZnjSc8-pkTNlvUD5dXvE3_KaLVfUxF4qil0N-8OvHqv7z5P8--ALQoXR0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)</title><source>Journals@Ovid Ovid Autoload</source><source>Alma/SFX Local Collection</source><creator>Giovannoni, Gavin ; Granziera, Cristina ; Mao-Draayer, Yang ; Cutter, Gary ; Kalbus, Oleksandr ; Staikov, Ivan ; Dufek, Michal ; Saubadu, Stephane ; Bejuit, Raphael ; Djukic, Biljana ; Truffinet, Philippe ; Wallstroem, Erik ; Vermersch, Patrick</creator><creatorcontrib>Giovannoni, Gavin ; Granziera, Cristina ; Mao-Draayer, Yang ; Cutter, Gary ; Kalbus, Oleksandr ; Staikov, Ivan ; Dufek, Michal ; Saubadu, Stephane ; Bejuit, Raphael ; Djukic, Biljana ; Truffinet, Philippe ; Wallstroem, Erik ; Vermersch, Patrick</creatorcontrib><description>Abstract only</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000205036</identifier><language>eng</language><ispartof>Neurology, 2024-04, Vol.102 (17_supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Giovannoni, Gavin</creatorcontrib><creatorcontrib>Granziera, Cristina</creatorcontrib><creatorcontrib>Mao-Draayer, Yang</creatorcontrib><creatorcontrib>Cutter, Gary</creatorcontrib><creatorcontrib>Kalbus, Oleksandr</creatorcontrib><creatorcontrib>Staikov, Ivan</creatorcontrib><creatorcontrib>Dufek, Michal</creatorcontrib><creatorcontrib>Saubadu, Stephane</creatorcontrib><creatorcontrib>Bejuit, Raphael</creatorcontrib><creatorcontrib>Djukic, Biljana</creatorcontrib><creatorcontrib>Truffinet, Philippe</creatorcontrib><creatorcontrib>Wallstroem, Erik</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><title>Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)</title><title>Neurology</title><description>Abstract only</description><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqdjzFPwzAQhS0EEqHwDxhuhMHFdtoksKJUDEARQYLNcsOZGlwn8gXRrPxyjIQYGHnLSe_dnd7H2LEUU6mkOnu8vZ6KXykxF3mxwzI5VwUvcvW0y7JkVzyvymqfHRC9CpHC8jxjn42xOIxgwjPU1rrWtCN0FhYRt8a7jVmBC3CP3vTkwgvcvPvB9R6haT3GjhxdwKziH4hvaYtSSmBjt4FhjXC3NoSgYNlj4N6s0EO9HTCQ6wKcNLlMrcvTQ7ZnjSc8-pkTNlvUD5dXvE3_KaLVfUxF4qil0N-8OvHqv7z5P8--ALQoXR0</recordid><startdate>20240409</startdate><enddate>20240409</enddate><creator>Giovannoni, Gavin</creator><creator>Granziera, Cristina</creator><creator>Mao-Draayer, Yang</creator><creator>Cutter, Gary</creator><creator>Kalbus, Oleksandr</creator><creator>Staikov, Ivan</creator><creator>Dufek, Michal</creator><creator>Saubadu, Stephane</creator><creator>Bejuit, Raphael</creator><creator>Djukic, Biljana</creator><creator>Truffinet, Philippe</creator><creator>Wallstroem, Erik</creator><creator>Vermersch, Patrick</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20240409</creationdate><title>Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)</title><author>Giovannoni, Gavin ; Granziera, Cristina ; Mao-Draayer, Yang ; Cutter, Gary ; Kalbus, Oleksandr ; Staikov, Ivan ; Dufek, Michal ; Saubadu, Stephane ; Bejuit, Raphael ; Djukic, Biljana ; Truffinet, Philippe ; Wallstroem, Erik ; Vermersch, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1212_WNL_00000000002050363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giovannoni, Gavin</creatorcontrib><creatorcontrib>Granziera, Cristina</creatorcontrib><creatorcontrib>Mao-Draayer, Yang</creatorcontrib><creatorcontrib>Cutter, Gary</creatorcontrib><creatorcontrib>Kalbus, Oleksandr</creatorcontrib><creatorcontrib>Staikov, Ivan</creatorcontrib><creatorcontrib>Dufek, Michal</creatorcontrib><creatorcontrib>Saubadu, Stephane</creatorcontrib><creatorcontrib>Bejuit, Raphael</creatorcontrib><creatorcontrib>Djukic, Biljana</creatorcontrib><creatorcontrib>Truffinet, Philippe</creatorcontrib><creatorcontrib>Wallstroem, Erik</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><collection>CrossRef</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giovannoni, Gavin</au><au>Granziera, Cristina</au><au>Mao-Draayer, Yang</au><au>Cutter, Gary</au><au>Kalbus, Oleksandr</au><au>Staikov, Ivan</au><au>Dufek, Michal</au><au>Saubadu, Stephane</au><au>Bejuit, Raphael</au><au>Djukic, Biljana</au><au>Truffinet, Philippe</au><au>Wallstroem, Erik</au><au>Vermersch, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)</atitle><jtitle>Neurology</jtitle><date>2024-04-09</date><risdate>2024</risdate><volume>102</volume><issue>17_supplement_1</issue><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>Abstract only</abstract><doi>10.1212/WNL.0000000000205036</doi></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2024-04, Vol.102 (17_supplement_1)
issn 0028-3878
1526-632X
language eng
recordid cdi_crossref_primary_10_1212_WNL_0000000000205036
source Journals@Ovid Ovid Autoload; Alma/SFX Local Collection
title Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31.007)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A56%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Frexalimab%20in%20Relapsing%20Multiple%20Sclerosis:%2048-week%20Results%20from%20the%20Phase%202%20Open-label%20Extension%20(S31.007)&rft.jtitle=Neurology&rft.au=Giovannoni,%20Gavin&rft.date=2024-04-09&rft.volume=102&rft.issue=17_supplement_1&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000205036&rft_dat=%3Ccrossref%3E10_1212_WNL_0000000000205036%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true